Demand for international pharma manufacturers and ingredients increasing in Russia

CPHI Russia 2016 opens as the country is seeking rapid upgrades to GMP standards.

The event is taking place at JSC VDNH (VVC), Moscow, 30 March–1 April 2016 and includes IPhEB Conference (forum), which provides key insights into the local market. One of the key sessions in this forum is a master class on strategy and procedure for companies and products ahead of market launch in the region. Market Access tactics and implementation will be developed at the master class, including how to evaluate the medical importance of a disease, therapeutic and pharma economic viability, its prevalence over the existing treatment methods, and availability.

Russia’s pharmaceutical market is positioned at the forefront of the pharma emerging markets, with the Government’s ambitious Pharma 2020 plan continuing apace, demand for international pharmaceutical ingredients, manufacturing and packaging equipment is increasing to upgrade existing manufacturing sites to GMP standards. Russia’s 2020 plan, introduced in 2009, provides direct investment by the Government, with nearly US$5 billion in funding, and the goal of increasing domestic finished-dose pharmaceutical manufacturing and R&D capabilities.

The country has attracted a strong base of international pharma companies — an overwhelming 76% of total pharmaceutical sales are attributed to imported drugs — with many more foreign manufacturers now looking to capitalise on this attractive market. Integral to the internationalization of this market is CPHI Russia, which acts a central hub for buyers and sellers within the region, providing a vital platform where pharma executives can connect, build and nurture existing relationships.

Growth in the domestic market has enabled CPHI Russia @ IPhEB to expand year-on-year, and in 2016, the three-in-one event will welcome more than 3000 attendees — in 2015, 231 exhibitors attended from 67 different countries. Exhibitors include some of the largest companies in pharmaceutical ingredients, machinery, equipment and technology (P-MEC), packaging and drug delivery systems (InnoPack), alongside domestic heavyweights Pharmasyntez, Indukern, Protek-SVM, Merck, Serdix, Kelun Kazfarm, and Sotex.

Robert Rosen, Director General of Selecta (RUS) Company, Bind (RUS), comments: "Last year was a very interesting event that facilitates the future development of science and pharmaceuticals. It helped our company to understand and find potential niches, research and administrative resources, and also business partners. CPHI Russia @ IPhEB provides all the opportunities for future, successful work. We are delighted to be returning to Moscow and actively contributing to new industry developments and Russia’s pharma expansion".

This year the highlights of the event include

Erick Heemsterk, Brand Director Pharma at UBM EMEA, commenting on the impact CPHI Russia @ IPhEB is having on the region: “2016 is the second year we have been based in Moscow and it enables us to be close to the Russian policy makers; the 2020 plan is one of the most important drivers for the Russian pharmaceutical industry. Russia is a complex market, but one ripe with future potential, and the content and market analysis at the event helps both domestic and international companies evaluate the opportunities. Whilst the CPHI exhibition facilitates the essential meetings in helping this market reach its full potential.